|Day Low/High||1.70 / 1.78|
|52 Wk Low/High||1.50 / 5.99|
Company Engages Expert Advisor Eric L. Curtis to Lead Internal Development Efforts and Manage External Partner Relationships
All Three Studies Submitted Were Selected for Poster Presentations
Additional Clinical Trials Evaluating Combinations with Aldoxorubicin Expected to Commence in 2018
Hires Investigation Firm to Initiate Short Selling Audit
Company's Goal is to Create a New Class of Rationally Designed, Breakthrough Anti-Cancer Drugs
Shares of Common Stock Will Begin Trading on a Post-Split Basis on November 1, 2017
Stockholders Approve Reverse Stock Split Proposal by More Than Double FOR to One AGAINST
Listing Extension Granted Pending Results of Stockholder Vote
- Authorized Common and Preferred Shares to be Reversed on Same One-for-Six Ratio as Issued and Outstanding Shares
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.